Abstract
Pulmonary aspergillosis has always been considered as a disease that occurs in patients with certain risk factors for its development. The COVID-19 pandemic has shown that fungal complications are common in patients without aspergillosis risk factors. Thus, invasive aspergillosis is a common complication of COVID-19. There are rare reports of aspergilloma that developed after a severe coronavirus infection in individuals who did not previously have cavitary lesions in the lungs. Development of aspergilloma as an expected long-term complication after COVID-19 may be due to damage of lung structure caused by coronavirus infection, oxygen therapy and mechanical ventilation. This article describes a case report of aspergilloma in a patient with confirmed severe COVID-19 and background chronic diseases without risk factors for fungal infection. A review of publications on the development of aspergilloma in patients following COVID-19 is also presented.
Omsk State Medical University, Omsk, Russia
Omsk State Medical University, Omsk, Russia
Clinical Medical and Surgical Center, Omsk, Russia
Clinical Medical and Surgical Center, Omsk, Russia
Clinical Medical and Surgical Center, Omsk, Russia
Clinical Medical and Surgical Center, Omsk, Russia
Clinical Medical and Surgical Center, Omsk, Russia
-
1.
World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int. Accessed March 03, 2022.
-
2.
Ministry of Health of the Russian Federation. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19): temporary guidelines. Version 16 (08/18/2022). Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/060/193/original/ВМР_COVID-19_V16.pdf. Accessed September 13, 2022. Russian.
-
3.
Bubnova M.G., Aronov D.M. COVID-19 and сardiovascular diseases: from epidemiology to rehabilitation. Pul’monologiya. 2020;30(5):688-699. Russian.
DOI: 10.18093/0869-0189-2020-30-5-688-699
-
4.
Lai C.-C., Yu W.-L. COVID-19 associated with pulmonary aspergillosis: a literature review. J Microbiol Immunol Infect. 2021;54(1):46-53.
DOI: 10.1016/j.jmii.2020.09.004
-
5.
Borman A.M., Palmer M.D., Fraser M., Patterson Z., Mann C., Oliver D., et al. COVID-19-associated invasive aspergillosis: data from the UK national mycology reference laboratory. J Clin Microbiol. 2020;59(1):e02136-20.
DOI: 10.1128/ JCM.02136-20
-
6.
Galstyan G.M. Coagulopathy in COVID-19. Pul’monologiya. 2020;30(5):645-657. Russian.
DOI: 10.18093/0869-0189-2020-30-5645-657
-
7.
Yaqinuddin A., Kashir J. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using monalizumab, cholroquine, and antiviral agents. Med Hypotheses. 2020;140:109777.
DOI: 10.1016/j.mehy.2020.109777
-
8.
Koehler P., Bassetti M., Chakrabarti A., Chen S.C.A., Colombo A.L., Hoenigl M., et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21(6):e149-162.
DOI: 10.1016/S1473-3099(20)30847-1
-
9.
Costantini C., van de Veerdonk F.L., Romani L. Covid-19associated pulmonary aspergillosis: the other side of the coin. Vaccines (Basel). 2020;8(4):713.
DOI: 10.3390/vaccines8040713
-
10.
Ovsjannikov N.V., Bilevich O.A. COVID-19 associated pulmonary aspergillosis. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2021;23(3):239-246. Russian.
DOI: 10.36488/cmac.2021.3.239-246
-
11.
Ovsjannikov N.V., Bilevich O.A., Zenkova L.A., Vasil’eva O.V. Invasive aspergillosis associated with COVID-19. Pul’monologija. 2021;31(5):671-676. Russian.
DOI: 10.18093/0869-0189-2021-31-5-671-676
-
12.
Chuchalin A.G., Ed. Pulmonology. National Guide. Short Edition. M.: GEOTAR-Media 2020. 768 p. Russian.
-
13.
Chaurasia S., Thimmappa M., Chowdhury S. Case report: chronic cavitatory pulmonary aspergillosis after COVID-19. Am J Trop Med Hyg. 2021;106(1):105-107.
DOI: 10.4269/ajtmh.21-0701
-
14.
Razafindrasoa Z.A., Ravahatra K., Tiaray H.M., Nandimbiniaina A.M., Andriamahenina F.P.P., Razafimpihanina S.M., et al. COVID-19 complicated with chronic necrotizing pulmonary aspergillosis and aspergilloma progressing to fibrosing aspergillosis: a case report. Clin Case Rep. 2022;10(5):e05814.
DOI: 10.1002/ccr3.5814
-
15.
Banke G., Kjeldgaard P., Shaker S.B., Sivapalan P., Sø‐ holm J., Holmgaard D.B., et al. Aspergilloma complicating previous COVID-19 pneumonitis – a case report. APMIS. 2022;130(7):397-403.
DOI: 10.1111/apm.13229